What is the Clinical Biomarkers & World CDx Europe Meeting?
The 11th Clinical Biomarkers & World CDx Europe once again united biomarker, diagnostic and precision medicine leaders to advance clinically predictive biomarkers to proven IVDs. Improving patient outcomes and standard of care, this meeting was built for biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver successful drug-Dx products.
Following the FDA’s approval of 12 personalised medicines and 7 diagnostics in 2019, then a record number of precision oncology drugs in H1 2020, demand is high for Dx-enabled therapies to reach the market. Despite the added pressures of the Covid-19 pandemic, in addition to a changing regulatory and fragmented environment, we are seeing significant progresses by pharma, academia and diagnostic expertise towards expediting the development of drugs in areas of great unmet medical need. It is now important that key stakeholders come together to share successes and lessons learnt to contextualise on advances and collaborate to deliver therapeutic advances in a more time effective manner.
Over the course of two days, the 11th annual Clinical Biomarkers & CDx Europe Summit brought together all stakeholders to fast-track precision medicine through clinically validated biomarkers and companion diagnostics partnerships in Europe. It tackled key conversations spanning biomarker discovery through to drug-Dx market penetration, enabling attendees with innovation to power pipeline progression and allowing them to hear and learn from true trailblazers on latest tools and techniques validating biomarker utility, overcoming patient selection challenges in rare disease, key clinical case-study learnings shaping diagnostic strategy in addition to the much needed core EU focus on navigating a tricky regulatory and reimbursement landscape to prevent incoming regulations hindering the delivery of critical drugs to patients in need.
Expert Speakers Included:
Head, Global Scientific Affairs, Innovation & Companion Diagnostics
Head, Executive Director, Global Regulatory Affairs, Translational Medicine & Devices
Precision Medicine Expert, Cardiovascular, Renal and Metabolism
Senior Medical Oncologist, Head of the Department of Drug Development and Innovation (D3i)
Vice President, Translational Medicine
Global Director Medical Affairs, Oncology, Thoracic & Pan Tumor Biomarkers & Diagnostics, Oncology Global Medical Affairs
Merck & Co.
Hear What Our Attendees Say
"This is the best platform for digital conference I have attended this year, you have set the bar in my mind."
“Fantastic organisation along with facilitation of effective networking. Conference content well thought through covering major discussion points within the field of Companion Diagnostics & Clinical Biomarkers.”
“It was great as ever, both from content as well as networking opportunity. The Hanson Wade Team has again done a great job.”
“The Hansonwade team are really on the ball when it comes to customer service, industry insights and understanding what makes an event work. Great location this year and look forward to the next event!”